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Ten years ago, in a paper called Britain’s Gift, the editor of the
BMJ at the time and the director of the UK Cochrane Centre
outlined a vision of medicine for the 21st century: easy access
to good quality reviews of clinical evidence, and the streamlined
recruitment of patients into randomised trials as a matter of
routine whenever there is uncertainty about choice of treatment.
“For example,” they explained: “we still do not know which
treatments are useful for acute stroke, but if every patient in the
world experiencing a stroke were admitted to trials we would
have enough patients within 24 hours to answer many of these
questions.”1
The first goal of easy access to good quality reviews of evidence
is on its way to being realised. Trials, however, remain
exceptional in everyday clinical care, and sometimes address
comparisons that are irrelevant to doctors and patients because
they compare new treatments with placebo rather than with the
best treatments currently available. Furthermore, trials are often
conducted in idealised or unrepresentative patient groups.2
Because of these problems, randomised trials commonly fail to
inform decisions in everyday clinical care: they address the
abstract question of an intervention’s efficacy under ideal
conditions, rather than its effectiveness when used in usual
clinical practice, on outcomes that are important to patients.3 4
Here we describe a UK project to implement randomised trials
as unobtrusively as possible in the everyday clinical work of
general practitioners (GPs), comparing treatments that are
already in common use, and using routinely collected electronic
healthcare records (EHR) both to identify participants and to
gather results. We discuss the rationale for this approach, the
potential for improving clinical evidence at low cost, and the
barriers encountered.
Opportunities for using EHR data for
randomised trials
Reports from both the Council for Science and Technology5
and from the Academy of Medical Sciences6 in 2005 and 2006
highlight the potential of EHR data for translational health
research, and research with EHR data has been recognised as a
key activity in the Department of Health’s national health
research strategy.7 Healthcare records are routinely stored on
computers in UK general practice (most people in the UK are
registered with a general practitioner). Some GP databases can
now be linked anonymously to other healthcare datasets,
including hospital admissions records, death certificates, and
disease registries. This record linkage system has been
implemented within the general practice research database
(GPRD) used in the trials presented here, and could be
implemented more widely. It allows long term, anonymous,
unobtrusive follow-up for major clinical outcomes, at low cost,
and with no extra time burden for the clinician, health service,
or patient.
Conventional trial recruitment is often problematic, with many
trials failing to meet their recruitment targets.8 The EHR
database may also be used to recruit patients into trials: it is
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searched to compile a list of potentially eligible patients, which
is sent securely to the clinician’s desktop computer. When a
patient on the eligibility list attends the practice for events
related to the trial, a flag appears on screen to notify the clinician
that the patient may be eligible for recruitment, with a link to
the study website. If patient and clinician agree to participate
and the GP confirms eligibility, the patient is randomised.
Table 1⇓ outlines the research questions, interventions, and
measurements in the first two feasibility trials for the randomised
evaluations of accepted choices in treatment (REACT) trials
that we are initiating. For these projects, there are daily
downloads of GP EHR into the GPRD. The trial database can
be compared periodically to the full research database for fraud
detection and generalisability of the randomised population.
A key requirement for the REACT trials is that so called usual
conditions apply as far as possible. Application of usual
conditions is important to ensure external validity, and also to
promote recruitment and retention: incompatibilities between
the protocols for randomised trials and usual clinical practice
can act as a barrier to recruitment.8 The studies we have outlined
are open label and non-blinded, with patients’ progress
monitored as usual in clinical practice, and these follow-up data
extracted from the EHR. The only added feature in pragmatic
randomised evaluations is that, among currently accepted
treatments where there is no evidence on comparative
effectiveness, treatment choices are based on random allocation
rather than on arbitrary decisions by clinicians.
Such uncertainty in choice of treatments remains common. For
many treatments in common use there is no evidence to inform
choice between available options, and, for most newmedicines,
evidence based assessment of any added therapeutic value is
not published at the time of market authorisation.9 The UK
database of uncertainties about the effects of treatments
(DUETs) was established to publish uncertainties about the
effects of treatments that cannot currently be answered by
referring to reliable, up to date, systematic reviews of existing
research evidence.10Where there is no evidence comparing two
commonly used treatments for the same condition, clinicians
and patients have no way of knowing which is the more
effective. In these circumstances, treatments are chosen
arbitrarily, through a non-scientific, haphazard process. Treating
patients in this arbitrary manner generates no new evidence to
improve clinical practice.
Where there is no evidence to guide the decisions of doctors
and patients, it is ethically acceptable and actively desirable to
offer willing patients the option of randomisation to assess which
treatment is preferable. General Medical Council guidance
requires doctors to resolve uncertainties about the effects of
treatments,11 and good medical practice requires that doctors
communicate evidence clearly to patients. Randomisation with
systematic data collection is the most rational and ethical way
to resolve uncertainties.12 13 Embedding randomised evaluations
within usual clinical practice can achieve this goal, and increase
the likelihood that clinicians will declare honestly to their
patients when there is uncertainty about the relative merits of
alternative treatment options.
In principle, as an ultimate goal, in every situation where there
is genuine uncertainty about which of two or more widely
accepted treatments is best, all willing patients could be offered
randomisation as part of routine clinical care, and their progress
followed up through EHR. If comparisons of accepted treatments
could be conducted within the routine clinical practice setting
in this fashion, the benefits would be considerable in terms of
new evidence, and cost effectiveness in research.14
Challenges with using EHR data for
randomised trials
The REACT approach does, however, face substantial
challenges (table 2⇓ lists opportunities and challenges, with
strategies to address them, for REACT trials conducted within
EHR databases). Firstly, andmost importantly, are current norms
in research governance. The requirements for informed consent
and regulatory oversight in all trials are time consuming and
expensive, even for trials comparing two interventions that have
already been shown to be safe and are in widespread and routine
use. This is a problem that has raised concerns over almost two
decades.15 Clinicians who admit there is uncertainty in a choice
between two interventions, and wish to address the uncertainty
by offering treatment in the context of a randomised evaluation,
are subject to intense regulatory scrutiny. Yet during routine
clinical care—in situations where there is no comparative
effectiveness research to guide treatment choice, so that
decisions are equally arbitrary—no such constraints apply.12
Experimentation by politicians on the delivery of health services
also does not suffer from this intense regulatory scrutiny.16
Several justifications have been suggested for so called research
exceptionalism—the phenomenonwherebymore stringent rules
are applied to research than to usual clinical practice, even for
treatments in widespread use. One frequently raised justification
is that research does not in general specifically aim to benefit
the participants, but rather to generate knowledge; study
participants may take the risks while others accrue the benefits.17
However, this justification often does not apply to patients with
chronic conditions, whose treatment next year may well benefit
from knowledge gained in the randomised evaluations they
participate in today. It is also unclear how a trial presents extra
risk, where the randomisation is between two routine treatments
already in widespread use, and with no evidence presently
available to inform a choice between them. This asymmetrical
approach to regulation can be traced back to the establishment
of the Declaration of Helsinki18 following the Nuremberg war
crimes trials.16 Informed consent is fundamental to medical
ethics, but the regulations designed to prevent abuse were never
intended to prevent evaluation of safety in routine practice.
In the REACT trials no new risks are introduced, but the
alternative—the current situation—has demonstrable ethical
problems. Good quality evidence to improve patient care cannot
be reliably generated from arbitrary treatment decisions made
in usual clinical practice, and patients may continue to suffer
through being exposed to interventions that are later found to
be inferior. Furthermore, where there is uncertainty clinical
decisions are often made without fully acknowledging their
arbitrariness to patients.
The extent to which research exceptionalism will restrict the
benefits of the REACT trials is not yet clear. All consent forms
currently cover a great deal of information normally not
provided when the same treatments are routinely given outside
a randomised evaluation, and are extremely time consuming to
complete. UK government guidelines presently recognise that
one size will not fit all with respect to the information that is
required to make autonomous decisions.19 However, the
guidelines also state that all randomised trials must comply with
the good clinical practice quality standard, and this includes a
list of 22 different topics to be covered in the information sheet.20
Research ethics committees may further add to this barrier, often
including idiosyncratic administrative requirements, such as a
duty on participants to inform a private health insurer (as
happened in our trials).
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We have concerns over these barriers to research on routine
treatments, which will reduce recruitment of clinicians and
patients. Requirements for informed consent should ideally be
based on empirical evidence on what kind of process best
informs participants, and be designed in collaboration with
patients. However, the good clinical practice quality standard,
which has come to be viewed as canonical, was based on expert
opinion, and has little empirical evidence. A systematic review
has found that evidence for the optimal amount of information
to enhance patient understanding is inconclusive and limited.21
UK government guidelines state that “any researcher is faced
with considerable difficulty” in selecting information for
informed consent, “given the disagreement on how much
information potential participants in research want.”19 There are
also frank contradictions. For example, the guidelines
recommend that draft versions of patient information sheets
should be passed to patients in disease support groups for
comments. But the same guidelines also require that all informed
consent procedures in trials must adhere to current good clinical
practice requirements,19 which mandate extensive content,20 so
support groups are prevented from reducing information
overload, for example, should they recommend this in their
comments.
This extra burden may reduce recruitment and retard research
throughout clinical medicine. The largest review conducted on
strategies to improve trial participation found that concerns
about extra effort and workload are barriers to recruitment for
both doctors and patients.22 The review also recommended that
trials should be framed and organised in ways that minimise
differences between research and clinical practice, using simple
and clear entry criteria, and address questions of clear relevance
to clinical practice.22
A second major challenge of using EHR data for trials is data
quality, which is of paramount importance. The REACT trials
will not be suited to evaluating every type of research question.
A study requiring detailed, study specific data collection at
regular intervals may not be best suited to a trial using EHR
data. There may also be specific outcomes that a trialist would
prefer to measure that are not routinely collected in EHR.
However, by definition many major outcomes are recorded in
routine medical notes. Furthermore, mortality and other major
clinical outcomes can now also be measured in EHR databases,
and then verified across several other data sources. As an
example, a heart attack in the REACT trials can be measured
in the GPRD, linked hospital data, disease registries, and death
certificates (if fatal). Where there is doubt, the patient’s clinician
can also be asked to confirm a diagnosis for an outcome of
interest.
Current progress of REACT trials
The first two REACT trials have recently been approved by the
research ethics committee, along with a qualitative study that
seeks feedback from GPs and patients to assess and improve
the implementation. The main point of discussion by the
committee was our proposed consent form. The original one
page patient information draft submitted for ethical review was
considered by the committee to be the “skimpiest ever” and
missing much of the standard clinical trial information (the
informed consent template of the UK National Research Ethics
Service lists a large number of items to be covered). We
resubmitted the patient information sheet, now twice the length
and amended to meet only the minimum ethics committee
requirements. It could be argued that the single most important
consideration for informed consent in the REACT trials should
be the replacement of clinician’s uncertainty with randomisation.
After all, the patient could have received any of the interventions
in a REACT trial by consulting another clinician.
The IT system has taken considerable time to develop and is
currently undergoing testing. Once implemented, the system
will provide instantaneous trial recruitment and daily analysis
of EHR data that can easily be adapted to future studies. GP
recruitment is also continuing. Of English GPRD practices, 42%
approached have expressed interest and 15% declined
(recruitment in Scotland has just started). Together with
recruitment by the Primary Care Research Network, we now
have over 200 interested practices, and study details (protocol
and contract) have now been sent to practices.
The main challenge now will be to obtain research and
development approvals from the 150 local NHS bodies that
cover UK general practices. Our experience with a GPRD cluster
trial23 and pharmacogenetic study found that this takes enormous
effort and time, even for low risk studies, replicated at multiple
sites, and often with differing systems. Our goal of maximising
representativeness is achieved by recruiting at multiple sites
with few patients in each, so such fragmented and diverse local
administrative systems present a challenge. Finally, the project
also has undertaken a review on how best to comply with the
good clinical practice quality standard, since this dispersed
model with electronic data collection means that site visits for
scrutiny are of very limited value.
Conclusions
EHR databases contain a wealth of information, and their utility
for randomised evaluations should be fully exploited. A
revolution is long overdue in the technical and research
governance frameworks for testing widely used interventions
whose relative merits are unknown. Narrowly restricted studies
with questionable external validity need not be the norm. Our
suggestion for large scale randomisation in usual clinical practice
may face several challenges, some of them technical, but most
of them related to research governance procedures. We hope
that these barriers will be overcome, by providing proof of
concept for a streamlined simple framework for undertaking
REACT trials, in which recognition of widespread uncertainties
about the effects of treatments will motivate clinicians and
patients to participate in randomised evaluations as a matter of
routine.
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Tables
Table 1| Research questions, interventions, and measurements in two feasibility REACT trials initiated within the GPRD
RETRO-PRO: the effectiveness of simvastatin compared to atorvastatin—a feasibility study (ISRCTN33113202)
Feasibility of REACT trials; pilot for comparative effectiveness of simvastatin and atorvastatin in patients with
primary hypercholesterolemia and high cardiovascular disease risk
Research questions
Randomisation between simvastatin and atorvastatin in 300 patients; non-blindedIntervention
Recruitment rates and technical challenges; changes in lipid levels at three months; duration of statin treatment
over time; long term incidence of myocardial infarction, stroke, and death (as measured in the GPRD, linked
hospital data, disease registry data, or death certificates)
Outcome measures
eLUNG: the effectiveness of antibiotics compared to no antibiotics for exacerbations of chronic obstructive pulmonary disease: a feasibility study
(ISRCTN72035428)
Feasibility of REACT trials; pilot for comparative effectiveness of antibiotics in patients with an exacerbation of
chronic obstructive pulmonary disease and non-purulent sputum
Research questions
Randomisation between antibiotic (whichever the general practitioner uses as first line) or usual care in 150
patients; non-blinded
Intervention
Recruitment rates and technical challenges; patient diary over four weeks of the exacerbations of chronic pulmonary
disease tool (EXACT-PRO) as completed on an electronic device; hospital admission over three months (as
measured in GPRD and linked hospital data); long term incidence of mortality (as measured in GPRD or linked
death certificates)
Outcome measures
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Table 2| Potential opportunities and challenges with REACT trials conducted within EHR databases
ChallengesOpportunities
Ethical and regulatory approvals—Approval has been achieved for pilot studies;
risk adapted regulatory processes may expedite approval for trials of routine
treatments in future
Long term follow-up at low cost—EHR database and linked datasets can be
used to follow study participants over the long term for major clinical outcomes
and mortality
Lengthy consent process—Ongoing research is necessary into the optimum length
of consent processes for informed patients; current practice will adversely affect
recruitment of clinicians and patients
Easy identification of eligible patients—Candidates are identified automatically
through the EHR database from a pool of all patients: clinician is alerted when
a patient they are treating meets eligibility criteria
Research approval at multiple local sites—Different regions have varying
requirements for research approval, which is resource intensive
Highly representative study populations—Randomisation at point of routine
care means safety and effectiveness of intervention is assessed in usual clinical
practice
Availability of desired outcome data in EHR—Feasibility of collecting additional
patient outcome data being assessed (eg, an electronic diary); REACT trials not
suited for studies that require major study specific data collection
Representativeness is measurable—Study population can be compared to
patients not enrolled in the trial
Data quality of EHR data—Recruitment can be restricted to patients with baseline
completeness of key covariates; linkages to external data sources permits validation;
outcomes can be restricted to outcomes well recorded in EHR
Adverse event monitoring—Daily transfer of EHR records into database: (i)
analyses in trial centre of suspected unexpected serious adverse reactions; (ii)
comparisons of event rates with those in patients not enrolled in trial
Trial drug supplies—Research focus is on current therapies prescribed as usual
by clinicians: no special supplies needed
Evaluation of research questions of direct relevance to clinicians—Trials only
of treatments already in routine use
Compliance with conventional good clinical practice (GCP) quality standard
requirements—With electronic records, there is no difference between data held
centrally and locally; a review is ongoing into optimum scrutiny methods for dispersed
electronic trials
Validation of major clinical outcomes—Confirmation of outcomes through the
linkages and/or by the patient’s clinician; blinded review of complete EHR by
experts
Clinician training in protocol and GCP—Online GCP training package is provided
for participating GPs
Recruitment for rarer conditions—Multiple sites offer a broader pool of potentially
eligible patients
Clinician time to recruit patients—New IT systems and strategies minimise time
and disruption; qualitative research of participating GP feedback is ongoing
Adaptive designs—Potential to incorporate minimisation during treatment
allocation
Lack of blinding of treatment allocation—REACT trials are best suited to measuring
major clinical outcomes with clear diagnostic criteria (such as death)
Testing of study strategies—Cluster randomisation of sites will allow evaluation
of study strategies (such as method of collection of additional data)
Cross over of study treatments over time—A challenge in most long term trials;
cross over may be outcome of interest (indicating treatment failure); statistical
techniques may partly deal with this
Fraud prevention—Newly registered patients not eligible; eligibility and
recruitment checks all recorded in the trial IT system; strategy to recruit few
patients at many sites
Local prescribing rules and performance indicators—GPs may operate under
mandatory or incentivised prescribing rules, without any exception for research
studies
Fraud detection—Clinical records of participants prior to and after the trial are
available to the trial investigators; outcomes from linked external sources not
controlled by local investigators (such as hospital episodes, mortality register)
Poor recognition of uncertainty by clinicians—If clinicians are unaware that current
practice lacks good quality evidence this may be a challenge for recruitment
Reduced loss to follow-up—Linkages will ensure that outcomes leading to
hospitalisation or death will be captured, even after a patient has left study site
Uncertainty faced by clinicians not recognised by researchers or funding
agencies—Clinicians need to be involved in setting a relevant research agenda
Linkage of patient data to EHR—Information collected by patients (for example,
using smart devices or electronic diaries) could be linked to outcome data
recorded in EHR
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